ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Ozols Promoted At Fox Chase; Greenberger Moves To Pittsburgh; ACR Names New Officers

October 8, 1993

NIh Clinical Center Urged To Create Governing Board

March 15, 1996

FDA Says ImClone Data Insufficient To Evaluate Colorectal Cancer Drug C225.

January 4, 2002

Cancer Letter On Vacation

August 3, 1984

Combine Phase 1-2, Abolish DRG, Slash Indirect Costs, Garb Tells Congress

November 27, 1981

NCAB Committee Approved Concepts For D Contracts

December 7, 1984